People at OncoStemyx
Vikash J. Bhagwandin
OncoStemyx has identified FDA approved drugs, not originally used for cancer, but combinations thereof can specifically target chemoresistant cancer stem cells.
Background
- OncoStemyX
CEO • 11 years
- UCSF-VAMC
Scientist, Oncology/Immuno-Oncology • 2 years
- UCSF Medical Center
Postdoctoral Fellowship, Oncology/Immuno-Oncology • 4 years